Table 2.

Demographic and pathological features by diagnosis

	Controls	Dystonia	PD	ET	SCA3	MSA	SCA1/2/6
N	25	14	29	50	6	15	17
Age at death (years)	75.3 ± 16.4 [80.0]	79.2 ± 9.2 [80.5] p = 0.57	78.0 ± 5.4 [79.0] p = 0.92	87.4 ± 6.3 [88.0] p = 0.001	55.5 ± 11.3 [59.0] p = 0.007	63.3 ± 9.3 [67.0] p = 0.01	58.9 ± 14.7 [63.0] p = 0.001
Male gender	15 (60.0%)	4 (28.6%) p = 0.06	22 (75.9%) p = 0.21	17 (34.0%) p = 0.03	2 (33.3) p = 0.37	5 (33.3%) p = 0.10	10 (58.8) p = 0.94
Brain weight (g)	1228 ± 176	1288 ± 100 p = 0.31	1342 ± 148 p = 0.01	1182 ± 135 p = 0.21	1235 ± 280 p = 0.96	1249 ± 97 p = 0.72	1159 ± 168 p = 0.22
Median (range) Thal stage for beta-amyloida	0 (0–2)	1.5 (0–2) p = 0.11	2 (0–2) p < 0.001	1 (0–2) p = 0.003	NA	0 (0–2) p = 0.95	NA
Median (range) Braak Alzheimer’s disease staging	1 (0–4)	2 (1–4) p = 0.11	3 (0–4) p < 0.001	2 (0–5) p = 0.001	NA	1 (0–4) p = 0.52	NA
Median (range) CERAD	0 (0–2)	0 (0–2) p = 0.24	1 (0–2) p = 0.016	1 (0–3) p = 0.08	NA	0 (0) p = 0.09	NA
Median postmortem interval (h)	4.5	NA	2.0 p = 0.07	2.3 p = 0.006	NA	0.9 p = 0.01	NA

Values are mean ± standard deviation [median] or number (percentage) unless otherwise specified. Statistical comparisons are with controls

Bolded values are statistically significant

Categorical or ordinal variables were compared using Chi-square tests. For continuous variables, we tested for normality using the Kolmogorov–Smirnov test. Continuous variables were compared using Student’s t tests or, if not normally distributed, a non-parametric test (i.e., Mann–Whitney)

CERAD Consortium to Establish a Registry for Alzheimer’s disease, ET essential tremor, MSA multiple system atrophy, NA not available, PD Parkinson’s disease, SCA spinocerebellar ataxia

^aCerebellum negative for beta-amyloid plaques by immunohistochemistry in all cases